Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.

doi:10.1016/j.jtho.2021.02.016

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2021

Finn Stephen P, Addeo Alfredo, Dafni Urania, Thunnissen Erik, Bubendorf Lukas, Madsen Line Bille, Biernat Wojciech, Verbeken Eric, Hernandez-Losa Javier, Marchetti Antonio, Cheney Richard, Warth Arne, Speel Ernst-Jan M, Quinn Anne Marie, Monkhorst Kim, Jantus-Lewintre Eloisa, Tischler Verena, Marti Nesa, Dimopoulou Georgia, Molina-Vila Miguel A, Kammler Roswitha, Kerr Keith M, Peters Solange, Stahel Rolf A

Abstract excerpt

INTRODUCTION: KRAS mutations, the most frequent gain-of-function alterations in NSCLC, are currently emerging as potential predictive therapeutic targets. The role of KRAS-G12C (Kr_G12C) is of special interest after the recent discovery and preclinical analyses of two different Kr_G12C covalent inhibitors (AMG-510, MRTX849). METHODS: KRAS mutations were evaluated in formalin-fixed, paraffin-embedded tissue...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Piperazines

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Source

Open in PubMed

Identifiers

PMID: 33647504
DOI: 10.1016/j.jtho.2021.02.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.PMID 33647504Read ↗

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.Semantic proximity Read ↗

Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.Semantic proximity Read ↗

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.Semantic proximity Read ↗

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

[Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].Semantic proximity Read ↗

Treating KRAS -mutant NSCLC: latest evidence and clinical consequencesSemantic proximity Read ↗

KRAS in NSCLC: State of the Art and Future PerspectivesSemantic proximity Read ↗

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.Semantic proximity Read ↗

KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent.Semantic proximity Read ↗

Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.Semantic proximity Read ↗

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).Semantic proximity Read ↗

Distinct molecular subtypes of KRASG12C-mutant lung adenocarcinoma: Insights into clinical outcomes, tumour microenvironments and therapeutic strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.